| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| Other Sizes |
| Targets |
NPC1L1 (Niemann-Pick C1-like1). Desfluoro-ezetimibe is a desfluoro impurity of ezetimibe, which is a potent inhibitor of NPC1L1. NPC1L1 is a transmembrane protein localized to the brush border membrane of enterocytes that mediates the intestinal absorption of cholesterol and phytosterols. By inhibiting NPC1L1, ezetimibe reduces cholesterol absorption from the intestine, lowering plasma cholesterol levels. Desfluoro-ezetimibe lacks the fluorine atom that is present in ezetimibe, which may affect its potency and metabolic stability. The compound is primarily used as an analytical reference standard rather than as a pharmacological agent.
|
|---|---|
| ln Vitro |
Reverse phase gradient high performance liquid chromatography (HPLC) was used to detect an impurity in the final product during the development studies of the synthetic process for ezetimibe, and LC-MS analysis was used to determine the impurity's molecular weight. The impurity was found at levels ranging from 0.05% to 0.15%. Desfluoro-ezetimibe is the impure substance[1].
The in vitro activity of Desfluoro-ezetimibe is primarily evaluated in the context of analytical chemistry rather than pharmacology. As an impurity of ezetimibe, the compound is used as a reference standard for HPLC and other analytical methods to quantify and characterize impurities in ezetimibe drug substance and drug products. The compound may have reduced potency as an NPC1L1 inhibitor compared to ezetimibe due to the absence of the fluorine atom, though specific potency data are not extensively reported in the available literature. |
| ln Vivo |
Desfluoro-ezetimibe is not a therapeutic agent and does not have intrinsic in vivo activity as a drug. It is an impurity that may be present in ezetimibe drug products and is monitored as part of quality control processes. The compound is used in metabolic and cardiovascular research as a reference standard.
|
| Enzyme Assay |
Characterization of Desfluoro-ezetimibe involves standard analytical techniques for small molecule impurities. Purity is typically assessed by HPLC, with the compound available at ≥99% purity. Nuclear magnetic resonance (NMR) spectroscopy (¹H and ¹³C) confirms the chemical structure, while mass spectrometry (MS) provides accurate molecular weight confirmation. The compound's molecular weight is 391.43 and its molecular formula is C24H22FNO3. The compound is a white to off-white solid. It is soluble in DMSO (slightly) and methanol (slightly). The compound may be stored at room temperature for short-term only.
|
| Cell Assay |
Cell-based studies with Desfluoro-ezetimibe are not typically performed, as the compound is an impurity standard rather than a pharmacological agent. When used in research, the compound may be evaluated for its effects on cholesterol uptake or NPC1L1 inhibition compared to ezetimibe.
|
| Animal Protocol |
In vivo studies with Desfluoro-ezetimibe are not typically performed, as the compound is an impurity standard rather than a pharmacological agent. The compound may be used as a reference standard in pharmacokinetic studies of ezetimibe to identify and quantify the desfluoro impurity in biological samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Desfluoro-ezetimibe are not extensively reported in the available literature. As an impurity of ezetimibe, the compound may have different metabolic stability and clearance compared to ezetimibe due to the absence of the fluorine atom. Storage recommendations include room temperature for short-term only; long-term storage conditions would need to be determined.
|
| Toxicity/Toxicokinetics |
Desfluoro-ezetimibe is an impurity standard and is not intended for human or veterinary use. Comprehensive toxicological data are not extensively reported in the available literature, as the compound is not a therapeutic agent. Standard laboratory safety precautions should be followed when handling the compound.
|
| References |
|
| Additional Infomation |
Desfluoro-ezetimibe is the defluorinated impurity of ezetimibe, a potent cholesterol absorption inhibitor that targets NPC1L1. It is widely used in metabolic and cardiovascular research as an analytical reference standard for quality control of ezetimibe-containing pharmaceutical products. The compound is not approved for clinical use and has no therapeutic indications. Synonyms include Desfluoroaniline Ezetimibe. The compound is available from multiple chemical suppliers.
|
| Molecular Formula |
C₂₄H₂₂FNO₃
|
|---|---|
| Molecular Weight |
391.43
|
| Exact Mass |
391.158
|
| CAS # |
302781-98-2
|
| Related CAS # |
302781-98-2
|
| PubChem CID |
58827445
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
642.8±55.0 °C at 760 mmHg
|
| Flash Point |
342.6±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
3.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C1=CC=C(C=C1)N2[C@@H]([C@H](C2=O)CC[C@@H](C3=CC=C(C=C3)F)O)C4=CC=C(C=C4)O
|
| InChi Key |
YWZUFJFIXFJKBD-XPWALMASSA-N
|
| InChi Code |
InChI=1S/C24H22FNO3/c25-18-10-6-16(7-11-18)22(28)15-14-21-23(17-8-12-20(27)13-9-17)26(24(21)29)19-4-2-1-3-5-19/h1-13,21-23,27-28H,14-15H2/t21-,22+,23-/m1/s1
|
| Chemical Name |
(3R,4S)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-1-phenylazetidin-2-one
|
| Synonyms |
Desfluoroezetimibe; Desfluoro ezetimibe; Desfluoro-ezetimibe
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5547 mL | 12.7737 mL | 25.5474 mL | |
| 5 mM | 0.5109 mL | 2.5547 mL | 5.1095 mL | |
| 10 mM | 0.2555 mL | 1.2774 mL | 2.5547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
